

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of CSE Issuer: Blueberries Medical Corp. (the "Company or "Issuer").

Trading Symbol: BBM

Number of Outstanding Listed Securities: 123,701,831

Date: **December 2019**

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**On December 3<sup>rd</sup>, the Issuer announced that it had commenced harvest of its first commercial crops at its 3.2-hectare Guatavita facility located in Bogotá Savannah, Colombia. The crops consist of the Company's five registered non-psychoactive cannabidiol ("CBD") strains recently approved by the Colombian Institute of Agriculture ("ICA"), as announced on September 27, 2019. These five proprietary cultivars were developed and tested by the Company's agronomy team and optimized for growth in the local climate as well as maximized active ingredient yield.**

#### **Key points:**

- 100 kg of dry flower have been harvested to date with growth cycle time and yields in line with expectations.
- An additional 3,400 plants are in the process of being harvested which will include approved cultivars and trial crops. The harvesting is scheduled to be completed by the end of 2019 with an expected yield of 400 to 500 kg of dry flower.
- Commercial production of CBD oil is expected to begin in the first quarter of 2020.

2. Provide a general overview and discussion of the activities of management.

**On November 27<sup>th</sup>, the Issuer filed its interim financial statements and management discussion and analysis for the quarter ended September 30<sup>th</sup>, 2019 on SEDAR and with the OTC.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**N/A**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**N/A**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**N/A**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**N/A**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**N/A**

8. Describe the acquisition of new customers or loss of customers.

**N/A**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**N/A**

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

**N/A**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**N/A**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**N/A**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**N/A**

14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**N/A**

16. Provide details of any changes in directors, officers or committee members.

**On December 16<sup>th</sup>, the Issuer announced that the Board of Directors has appointed Mr. Camilo Villalba as Chief Executive Officer of the Company. Mr. Villalba, who is a co-founder of Blueberries and currently serves as Chief Operating Officer, will lead the Company's next phase of operational development, with initial exports expected during the first half of 2020. Dr. Patricio Stocker will continue to support Blueberries as a Senior Strategic Consultant focused on expanding the Company's international cannabis sales and other strategic initiatives.**

**Mr. Villalba is a co-founder of Blueberries and has been leading the corporate and operational areas since before the Company became the first Colombian cannabis producer listed on the Canadian Securities Exchange. An**

entrepreneur and business strategist, Mr. Villalba began his career in the Energy sector, providing consulting services to diverse companies in Latin America. Before founding Blueberries, Mr. Villalba was a private equity investor and supported the creation and growth of ventures in different Latin American markets, including Colombia and Mexico. Mr. Villalba has lived and worked in several cities around the globe, developing a robust international business network.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**N/A**

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 7, 2020.

Ian D. Atacan

**Name of Director or Senior Officer**

"Ian D. Atacan"

**Signature**

Chief Financial Officer

**Official Capacity**

<b>Issuer Details</b>	For Month	Date of Report
Name of Issuer	End	YY/MM/DD
Blueberries Medical Corp.	December	
	2019	2020/01/07
Issuer Address		
885 West Georgia Street, Suite 2200, HSBC Building		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 3E8		
Contact Name	Contact Position	Contact Telephone No.
Ian Atacan	CFO	(416) 562-3220
Contact Email Address	Web Site Address	
<a href="mailto:iatacan@blueberriesmed.com">iatacan@blueberriesmed.com</a>	<a href="http://www.blueberriesmed.com">www.blueberriesmed.com</a>	